Evidence map›Paper›PMID 37017445›Full record

ReviewPharmaceuticals (Basel, Switzerland)2023

Endocannabinoid System: Chemical Characteristics and Biological Activity.

Bismarck Rezende, Allan Kardec Nogueira Alencar, Graziele Freitas de Bem, Fabrícia Lima Fontes-Dantas, Guilherme Carneiro Montes

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
16.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Observational
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Bismarck RezendeDepartment of Pharmacology and Psychobiology, Roberto Alcântara Gomes Institute Biology (IBRAG), Rio de Janeiro State University (UERJ), Rio de Janeiro 20551-030, Brazil.ORCID 0000-0002-4005-6493
Allan Kardec Nogueira AlencarDepartment of Biomedical Engineering, Tulane University, New Orleans, LA 70118, USA.ORCID 0000-0002-3072-6270
Graziele Freitas de BemDepartment of Pharmacology and Psychobiology, Roberto Alcântara Gomes Institute Biology (IBRAG), Rio de Janeiro State University (UERJ), Rio de Janeiro 20551-030, Brazil.
Fabrícia Lima Fontes-DantasDepartment of Pharmacology and Psychobiology, Roberto Alcântara Gomes Institute Biology (IBRAG), Rio de Janeiro State University (UERJ), Rio de Janeiro 20551-030, Brazil.ORCID 0000-0002-5201-0927
Guilherme Carneiro MontesDepartment of Pharmacology and Psychobiology, Roberto Alcântara Gomes Institute Biology (IBRAG), Rio de Janeiro State University (UERJ), Rio de Janeiro 20551-030, Brazil.ORCID 0000-0003-4946-9056
Universidade do Estado do Rio de Janeiro · BRTulane University · US

Funding

Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/211.795/2021
6 · The paper itself

Abstract

The endocannabinoid system (eCB) has been studied to identify the molecular structures present in

Indexed as

chronic painendocannabinoid ligandsendocannabinoid systemintegrative and complementary health practicesmood disordersphytocannabinoidsreceptor cannabinoid

Identifiers

PMID37017445
PMCPMC9966761
OpenAlexW4317434652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.